Table 3. Sub Group Analysis of Primary Outcome (Clinical Cure at 3 Weeks).

	Benzathine penicillin (95% CI)	Azithromycin (95% CI)	Risk difference % (95%CI)
Clinical Stage of yaws:
Primary	98.7(96.2–100)	98.9(96.7–100)	-0.2(-3.4 to 3.1)
Secondary	95.0(90.1–99.9)	97.5(93.9–100)	-2.5(-8.4 to 3.4)
Baseline RPR titre:
1:4–1:16	93.7(87.5–99.7)	98.6(96.0–100)	-5.0(-11.6 to 1.6)
1:32–1:128	99.0(96.7–100)	97.9(95.0–100)	1.1(-12.5 to 4.6)
Household Exposure:
Exposed	98.7(96.1–100)	92.6(94.2–100)	1.1(-3.4 to 5.3)
Not exposed	95.1(90.2–99.9)	98.8(96.5–100)	-3.8(-9.0 to1.5)